The association of antiphospholipid syndrome under medical treatment with adverse pregnancy outcomes.

IF 1.3 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Journal of Perinatal Medicine Pub Date : 2025-11-27 Print Date: 2026-03-26 DOI:10.1515/jpm-2025-0156

Huilin Tang, Mingjie Xiang

{"title":"The association of antiphospholipid syndrome under medical treatment with adverse pregnancy outcomes.","authors":"Huilin Tang, Mingjie Xiang","doi":"10.1515/jpm-2025-0156","DOIUrl":null,"url":null,"abstract":"Objectives: We aim to clarify the association and strength of association between antiphospholipid syndrome (APS) and adverse pregnancy outcomes.Methods: Our study included an analysis of 191 hospitalized singleton pregnant women with APS and 984 healthy singleton pregnant women at Obstetrics and Gynecology Hospital Affiliated to Fudan University from July 2017 to September 2023. The exposure factor was diagnosed as antiphospholipid syndrome, and the main outcomes were adverse pregnancy outcomes, including miscarriage, preterm birth, low birth weight, gestational hypertension, and eclampsia.Results: Our analysis indicated that the odds ratio (OR) for miscarriage in APS patients was 2.50 (95 % CI, 1.025 ± 15.794; p=0.046), for preterm birth was 2.8 (95 % CI, 1.025 ± 15.794; p=0.046), for low birth weight was 2.28 (95 % CI, 1.025 ± 15.794; p=0.046), and for fetal growth restriction was OR=2.48 (1.45, 4.23) p<0.05. The OR for preeclampsia was 1.00, and for gestational hypertension was 0.96, p>0.05. After adjustment for confounders of age and BMI confounders, the odds ratio (OR) for miscarriage was 2.50 (95 % CI: 1.52-4.11) p<0.05. Preterm birth was 2.89 (95 % CI: 1.79-4.65) p<0.05, low birth weight was 2.28 (95 % CI: 1.52-3.55) p<0.05, intrauterine growth restriction was 2.48 (95 % CI: 1.45-4.23) p<0.05. The OR of preeclampsia was 1.00 (95 % CI: 0.59-1.71) p>0.05, and that of pregnancy-induced hypertension was 0.96 (95 % CI: 0.53-1.75) p>0.05. After adjustment for confounders of age, BMI, eclampsia and diabetes, the OR for preterm infants were 3.06 (95 % CI: 1.87-5.00) p<0.05, and those of low birth weight infants were 2.55 (95 % CI: 1.49-4.37) p<0.05. After adjustment for confounders of age, BMI, diabetes, eclampsia, and gestational week, the OR for low birth weight infants was 2.02 (95 % CI: 1.26-3.26) p<0.05.Conclusions: Antiphospholipid syndrome was significantly associated with the risk of miscarriage, preterm birth, low birth weight, and intrauterine growth restriction as adverse pregnancy outcomes.","PeriodicalId":16704,"journal":{"name":"Journal of Perinatal Medicine","volume":" ","pages":"515-521"},"PeriodicalIF":1.3000,"publicationDate":"2025-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Perinatal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/jpm-2025-0156","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/26 0:00:00","PubModel":"Print","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: We aim to clarify the association and strength of association between antiphospholipid syndrome (APS) and adverse pregnancy outcomes.

Methods: Our study included an analysis of 191 hospitalized singleton pregnant women with APS and 984 healthy singleton pregnant women at Obstetrics and Gynecology Hospital Affiliated to Fudan University from July 2017 to September 2023. The exposure factor was diagnosed as antiphospholipid syndrome, and the main outcomes were adverse pregnancy outcomes, including miscarriage, preterm birth, low birth weight, gestational hypertension, and eclampsia.

Results: Our analysis indicated that the odds ratio (OR) for miscarriage in APS patients was 2.50 (95 % CI, 1.025 ± 15.794; p=0.046), for preterm birth was 2.8 (95 % CI, 1.025 ± 15.794; p=0.046), for low birth weight was 2.28 (95 % CI, 1.025 ± 15.794; p=0.046), and for fetal growth restriction was OR=2.48 (1.45, 4.23) p<0.05. The OR for preeclampsia was 1.00, and for gestational hypertension was 0.96, p>0.05. After adjustment for confounders of age and BMI confounders, the odds ratio (OR) for miscarriage was 2.50 (95 % CI: 1.52-4.11) p<0.05. Preterm birth was 2.89 (95 % CI: 1.79-4.65) p<0.05, low birth weight was 2.28 (95 % CI: 1.52-3.55) p<0.05, intrauterine growth restriction was 2.48 (95 % CI: 1.45-4.23) p<0.05. The OR of preeclampsia was 1.00 (95 % CI: 0.59-1.71) p>0.05, and that of pregnancy-induced hypertension was 0.96 (95 % CI: 0.53-1.75) p>0.05. After adjustment for confounders of age, BMI, eclampsia and diabetes, the OR for preterm infants were 3.06 (95 % CI: 1.87-5.00) p<0.05, and those of low birth weight infants were 2.55 (95 % CI: 1.49-4.37) p<0.05. After adjustment for confounders of age, BMI, diabetes, eclampsia, and gestational week, the OR for low birth weight infants was 2.02 (95 % CI: 1.26-3.26) p<0.05.

Conclusions: Antiphospholipid syndrome was significantly associated with the risk of miscarriage, preterm birth, low birth weight, and intrauterine growth restriction as adverse pregnancy outcomes.

查看原文本刊更多论文

药物治疗中的抗磷脂综合征与不良妊娠结局的关系

目的：我们旨在阐明抗磷脂综合征（APS）与不良妊娠结局之间的关联及其强度。方法：对2017年7月至2023年9月复旦大学附属妇产科医院住院的191例APS单胎孕妇和984例健康单胎孕妇进行分析。暴露因素诊断为抗磷脂综合征，主要结局为不良妊娠结局，包括流产、早产、低出生体重、妊娠期高血压、子痫。结果：我们的分析显示，APS患者流产的优势比（OR）为2.50(95 % CI, 1.025±15.794;p=0.046)，早产的优势比（OR）为2.8(95 % CI, 1.025±15.794;p=0.046)，低出生体重的优势比（OR）为2.28(95 % CI, 1.025±15.794;p=0.046)，胎儿生长受限的优势比（OR）为2.48 (1.45,4.23),p0.05。在调整年龄和BMI混杂因素后，流产的优势比（OR）为2.50(95 % CI: 1.52 ~ 4.11) p0.05，妊娠高血压的优势比（OR）为0.96(95 % CI: 0.53 ~ 1.75) p >.05。在调整了年龄、BMI、子痫和糖尿病等混杂因素后，早产儿的OR为3.06（95 % CI: 1.87-5.00）。结论：抗磷脂综合征与流产、早产、低出生体重和宫内生长受限等不良妊娠结局的风险显著相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Perinatal Medicine 医学-妇产科学

CiteScore

4.40

自引率

8.30%

发文量

183

审稿时长

4-8 weeks

期刊介绍： The Journal of Perinatal Medicine (JPM) is a truly international forum covering the entire field of perinatal medicine. It is an essential news source for all those obstetricians, neonatologists, perinatologists and allied health professionals who wish to keep abreast of progress in perinatal and related research. Ahead-of-print publishing ensures fastest possible knowledge transfer. The Journal provides statements on themes of topical interest as well as information and different views on controversial topics. It also informs about the academic, organisational and political aims and objectives of the World Association of Perinatal Medicine.